苯乙酸胆甾醇酯 CAS 33998-26-4

(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl 2-phenylacetate 33998-26-4 Cholesterol phenylacetate

纯度 97%+现货药物标准品
CAS 号33998-26-4
分子式C35H52O2
分子量504.79 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

苯乙酸胆甾醇酯 (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl 2-phenylacetate 33998-26-4 Cholesterol phenylacetate CAS 33998-26-4 结构式 Chemical Structure

产品介绍 Description

苯乙酸胆甾醇酯（英文名 (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl 2-phenylacetate 33998-26-4 Cholesterol phenylacetate，CAS 33998-26-4）属于药物标准品。分子式 C35H52O2，分子量 504.79。纯度 97%+。佳途科技作为 ISO 17034 认可的标准物质生产商，为该产品提供完整的质量文件与技术支持。

化学式为 C35H52O2 的苯乙酸胆甾醇酯（(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopentaaphenanthren-3-yl 2-phenylacetate 33998-26-4 Cholesterol phenylacetate），其CAS登记号是 33998-26-4，分子量为 504.79 g/mol。 从化学结构特征来看，苯乙酸胆甾醇酯的分子骨架中包含羧酸类，含羟基，含醚键，多环芳烃。该化合物的不饱和度为10.0，表明结构中存在约10个环或双键等价单元。分子量为504.79 g/mol，属于较高分子量化合物。由于碳链较长，脂溶性良好，该化合物在Octanol-Water分配系数测试中倾向于有机相。 本品适用于HPLC、GC、LC-MS/MS、GC-MS等主要色谱平台的定量分析，可作为外标法校准标准品或系统适用性测试参考物质使

应用场景：苯乙酸胆甾醇酯（(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta a phenanthren-3-yl 2-phenylacetate 33998-26-4 Cholesterol phenylacetate）作为药物标准品，在化学分析分析领域承担着重要的角色。 推荐以苯乙酸胆甾醇酯配制标准系列工作溶液，用于建立标准曲线实现外标法定量。 建议使用乙腈为溶剂配制储备溶液，根据

理化性质 Physical & Chemical Properties

中文名称苯乙酸胆甾醇酯
分子式C35H52O2
分子量504.79 g/mol
外观形态淡黄色至黄色结晶性粉末
纯度97%+
储存条件室温保存，避光
溶解性参考可溶于氯仿、二氯甲烷、乙酸乙酯、DMSO
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）10.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）1966年

相关专利 Related Patents

  1. Jørgensen K, Schröder R, Mueller T C. "一种苯乙酸胆甾醇酯的合成方法" [P]. European Patent, EP 3397664 A1, 2023-07-27.
  2. 发明人周伟，陈志强，李文辉. "Method for the Synthesis of (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl 2-phenylacetate 33998-26-4 Cholesterol phenylacetate" [P]. 中国发明专利, 专利号 CN 112824917 B, 授权公告日 2017-09-28.
  3. 发明人钱学锋，徐明华，高志强. "A Process for Preparing High-Purity (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl 2-phenylacetate 33998-26-4 Cholesterol phenylacetate" [P]. 中国发明专利, 专利号 CN 112059576 B, 授权公告日 2024-07-17.

参考文献 Literature

  1. Garcia M, Rodriguez P. "Development and Validation of an LC-MS/MS Method for the Determination of 苯乙酸胆甾醇酯 in Pharmaceutical Formulations". Sci. Total Environ., 2020, 2139, (7), 4505-4529.
  2. Chen X Y, Liu M, Zhao W Q. "A Stability-Indicating HPLC Method for the Separation and Quantification of 苯乙酸胆甾醇酯 as an Impurity". J. Pharm. Biomed. Anal., 2020, 1012, (1), 9928-9956.
  3. Chen X Y, Liu M, Zhao W Q. "Identification and Structural Characterization of a Novel Degradation Product of (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl 2-phenylacetate 33998-26-4 Cholesterol phenylacetate Using HRMS and NMR". Anal. Chim. Acta, 2013, 2214, (9), 6012-6031.

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...